Andrew Carter, DO
Interventional Cardiology · Hays, KSNPI 1700859659
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,674 of the $2,573 with a category attached, or 65.1%. 16 manufacturers reported payments, led by Medtronic at 43.9% of the total. Reporting peaked in 2019 at $1,208 and has fallen 82.0% since, to $217 in 2025. That places this record below the midpoint for interventional cardiology clinicians in KS, where the typical reported total is $8,846.
Across 61 payments — averaging $42.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novartis$331
- Medicure Pharma Inc.$205
- Inspire Medical Systems, Inc.$198
- Abbott$184
- Boston Scientific$130
- plus $395 from 10 others
What the payments were for
- Travel & lodging$89935%
- Food & beverage$1,67465%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $1,129 |
| Novartis | 16 | $331 |
| Medicure Pharma Inc. | 1 | $205 |
| Inspire Medical Systems, Inc. | 5 | $198 |
| Abbott | 7 | $184 |
| Boston Scientific | 6 | $130 |
| Abiomed | 5 | $124 |
| Chiesi USA, Inc. | 4 | $78 |
| Amgen | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Cvrx, Inc. | 2 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Pfizer | 1 | $17 |
| Change Healthcare Technologies, LLC | 1 | $15 |
| Teleflex LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,573 in reported general payments places this provider in the 15th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $147,923 |
| XareltoRivaroxaban | 38 | $41,518 |
| JardianceEmpagliflozin | 35 | $40,323 |
| EntrestoSacubitril/Valsartan | 13 | $23,102 |
| Metoprolol Succinate | 178 | $2,484 |
| Atorvastatin Calcium | 200 | $2,338 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $1,138 |
| Ezetimibe | 45 | $1,105 |
| Rosuvastatin Calcium | 100 | $1,076 |
| Lisinopril | 95 | $821 |
| Valsartan | 36 | $800 |
| Losartan Potassium | 74 | $731 |
| Bumetanide | 23 | $667 |
| Spironolactone | 50 | $553 |
| ClopidogrelClopidogrel Bisulfate | 36 | $437 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $147,923124 claims |
| NovartisEntresto | $331 | $23,10213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Hays
- Travis HanekeHays$21K
- Niranjan SeshadriHays$3K
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Priyantha RanaweeraManhattan$41K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.